Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis – proposal to defer consideration of the review

Proposal to defer consideration of the review

The planned date for review of the above guidance was June 2010.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full appraisal review.

The Institute has carried out a search for information relevant to this appraisal, and has found that to the best of its knowledge, no new evidence has been published that would have a material effect on the original guidance. However, we are aware of a trial which is due to report in 2013. Consequently we propose that the review of the original guidance be deferred until 2013 at which point the review of TA127 will be considered along with that of TA32; Beta interferon and glatiramer for multiple sclerosis. TA32 is currently classed as static guidance and should remain static until the combined review is considered in 2013.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance. Please see appendix A for a full list of the organisations we have contacted.

October 2010